Etavopivat

Etavopivat is a potent, selective, and orally active erythrocyte pyruvate kinase (PKR) activator. Etavopivat has potent antisickling effects that can be used in studies of sickle cell disease and other haemoglobinopathies[1][2].

Product Specifications

CAS Number

[2245053-57-8]

Product Name Alternative

FT-4202

UNSPSC

12352005

Target

Pyruvate Kinase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/etavopivat.html

Concentration

10mM

Purity

99.91

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=S(N1CC2=C(CN(C2)C([C@@H](C3=CC=CC=C3)CO)=O)C1)(C4=CN=C(OCCO5)C5=C4)=O

Molecular Formula

C22H23N3O6S

Molecular Weight

457.50

References & Citations

[1]Shrestha A, et al. FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice. Blood Adv. 2021 May 11;5 (9) :2385-2390.|[2]Schroeder P, et al. Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease. J Pharmacol Exp Ther. 2022 Mar;380 (3) :210-219.